MCID: TRC008
MIFTS: 52

Trachoma

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Trachoma

MalaCards integrated aliases for Trachoma:

Name: Trachoma 12 72 49 51 41 14 69
Trachoma, Initial Stage 69
Trachoma, Active Stage 69
Active Stage Trachoma 12
Trachoma Dubium 12

Classifications:



Summaries for Trachoma

Disease Ontology : 12 A commensal bacterial infectious disease that results_in infection located in eye, has material basis in Chlamydia trachomatis (A, B, Ba and C serovars), which is transmitted_by contact with eye discharge from the infected person and transmitted_by congenital method. The infection causes eyelid to turn inward which makes eyelashes to scratch the cornea.

MalaCards based summary : Trachoma, also known as trachoma, initial stage, is related to chlamydia and onchocerciasis. An important gene associated with Trachoma is KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3), and among its related pathways/superpathways are Immune response Role of DAP12 receptors in NK cells and Tuberculosis. The drugs Azithromycin and Permethrin have been mentioned in the context of this disorder. Affiliated tissues include eye, eye and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Trachoma is an infectious disease caused by bacterium Chlamydia trachomatis. The infection causes a... more...

Related Diseases for Trachoma

Diseases related to Trachoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 chlamydia 31.5 HSPD1 IDO1 IL10 TNF
2 onchocerciasis 11.4
3 entropion 11.3
4 conjunctivitis 10.5
5 inclusion conjunctivitis 10.4
6 localized scleroderma 10.3 CTGF TNF
7 sympathetic ophthalmia 10.3 HLA-C TNF
8 lymphogranuloma venereum 10.3
9 geographic tongue 10.3 HLA-C TNF
10 punctate inner choroidopathy 10.3 IL10 TNF
11 tropical endomyocardial fibrosis 10.2 IL10 TNF
12 microscopic polyangiitis 10.2 IL10 TNF
13 multifocal choroiditis 10.2 IL10 TNF
14 headache 10.2 IDO1 TNF
15 tungiasis 10.2 IL10 TNF
16 endomyocardial fibrosis 10.2 IL10 TNF
17 transient hypogammaglobulinemia 10.2 IL10 TNF
18 choroiditis 10.2 IL10 TNF
19 mucocutaneous leishmaniasis 10.2 IL10 TNF
20 idiopathic achalasia 10.2 IL10 TNF
21 clonorchiasis 10.2 IL10 TNF
22 orofacial granulomatosis 10.2 IL10 TNF
23 poliomyelitis 10.2 IL10 TNF
24 transverse myelitis 10.2 IL10 TNF
25 primary systemic mycosis 10.2 IL10 TNF
26 intermediate uveitis 10.2 IL10 TNF
27 immune suppression 10.2 IDO1 IL10
28 multidrug-resistant tuberculosis 10.2 IL10 TNF
29 post-transplant lymphoproliferative disease 10.2 IL10 TNF
30 coccidiosis 10.2 IL10 TNF
31 eales disease 10.2 IL10 TNF
32 hemorrhagic fever 10.2 IL10 TNF
33 chronic active epstein-barr virus infection 10.2 IDO1 IL10
34 aseptic meningitis 10.2 IL10 TNF
35 spotted fever 10.2 IL10 TNF
36 panuveitis 10.2 IL10 TNF
37 scrub typhus 10.2 IL10 TNF
38 cytomegalovirus infection 10.2 IL10 TNF
39 plasmodium vivax malaria 10.2 IL10 TNF
40 q fever 10.2 IL10 TNF
41 aging 10.2
42 viral encephalitis 10.2 IL10 TNF
43 aphthous stomatitis 10.2 IL10 TNF
44 epstein-barr virus-associated gastric carcinoma 10.2 IL10 TNF
45 churg-strauss syndrome 10.2 IL10 TNF
46 severe hemophilia a 10.2 IL10 TNF
47 lepromatous leprosy 10.2 IL10 TNF
48 hemorrhagic fever with renal syndrome 10.1 IL10 TNF
49 extrinsic cardiomyopathy 10.1 IL10 TNF
50 acute graft versus host disease 10.1 IL10 TNF

Graphical network of the top 20 diseases related to Trachoma:



Diseases related to Trachoma

Symptoms & Phenotypes for Trachoma

GenomeRNAi Phenotypes related to Trachoma according to GeneCards Suite gene sharing:

25 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.9 HSPD1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.9 KIR2DL2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.9 HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.9 KIR2DL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.9 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.9 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.9 KIR2DL2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.9 KIR2DL2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.9 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.9 HSPD1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.9 KIR2DL2 HSPD1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.9 KIR2DL2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.9 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.9 HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.9 HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.9 KIR2DL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.9 HSPD1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.9 KIR2DL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.9 HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.9 HLA-C
21 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.9 KIR2DL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.9 KIR2DL2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.9 HLA-C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.9 HLA-C
25 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.9 HLA-C
26 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.9 KIR2DL2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.9 KIR2DL2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.9 HSPD1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.9 KIR2DL2 HLA-C
30 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.9 KIR2DL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.9 KIR2DL2 HLA-C
32 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.9 KIR2DL2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.9 KIR2DL2 HLA-C HSPD1

MGI Mouse Phenotypes related to Trachoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.02 ENG HSPD1 IDO1 IL10 TNF

Drugs & Therapeutics for Trachoma

Drugs for Trachoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 53477736 447043 55185
2
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
3
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
4
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
5
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 46936176 6474909
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
7
Sulfamethoxazole Approved Phase 4 723-46-6 5329
8
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
9 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
10 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
11 Anti-Infective Agents Phase 4
12 Anthelmintics Phase 4
13 Antimitotic Agents Phase 4
14 Antiparasitic Agents Phase 4
15 Antiprotozoal Agents Phase 4
16 Antitubercular Agents Phase 4
17 Antimalarials Phase 4
18 Renal Agents Phase 4
19 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
20 Ophthalmic Solutions Phase 3
21 Pharmaceutical Solutions Phase 3
22 Tetrahydrozoline Phase 3
23
Menthol Approved 2216-51-5 16666
24
Fluorometholone Approved, Investigational 426-13-1 9878
25 Anti-Allergic Agents
26 Anti-Inflammatory Agents
27 glucocorticoids
28 Hormone Antagonists
29 Hormones
30 Hormones, Hormone Substitutes, and Hormone Antagonists
31 Lubricant Eye Drops

Interventional clinical trials:

(show all 32)

# Name Status NCT ID Phase Drugs
1 Partnership for Rapid Elimination of Trachoma Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
2 Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania Completed NCT00347607 Phase 4
3 Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Completed NCT00347763 Phase 4
4 Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
5 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
6 Trachoma Elimination Follow-up Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
7 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
8 Trachoma Amelioration in Northern Amhara (TANA) Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
9 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
10 Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia Completed NCT00347776 Phase 4 azithromycin;topical tetracycline
11 Mortality Reduction After Oral Azithromycin: Morbidity Study Completed NCT02048007 Phase 4 Azithromycin;Placebo
12 Mortality Reduction After Oral Azithromycin: Mortality Study Completed NCT02047981 Phase 4 Azithromycin;Placebo
13 Sanitation, Water, and Instruction in Face-washing for Trachoma Recruiting NCT02754583 Phase 4 Azithromycin;Tetracycline;Albendazole
14 Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children Recruiting NCT02414399 Phase 4 Azithromycin;Placebo
15 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso Active, not recruiting NCT03187834 Phase 4 Azithromycin;Amoxicillin;Cotrimoxazole;Placebo
16 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
17 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
18 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
19 Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3 Azithromycin
20 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
21 Nepal Elimination of Trachoma Study Withdrawn NCT02176057 Phase 2, Phase 3 Azithromycin
22 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Completed NCT01767506
23 The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis Completed NCT01178762 Azithromycin
24 Modified Instrumentation for Surgery to Correct Trichiasis Completed NCT00886015
25 Water Uptake for Health in Amhara Pilot Completed NCT02373657
26 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
27 Identification of TT Cases by Community Treatment Assistants: An Assessment Completed NCT01783743
28 Fluorometholone as Ancillary Therapy for TT Surgery Completed NCT01949454 Fluorometholone 0.1% ophthalmic solution
29 A Trial of Epilation Verses Surgery for Minor Trichiasis Completed NCT00522912
30 Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze Completed NCT00439114
31 The Effect of Long-Term HEAD START Training on Surgical Skill Levels Active, not recruiting NCT03135080
32 Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Withdrawn NCT02655432 Early Phase 1

Search NIH Clinical Center for Trachoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: trachoma

Genetic Tests for Trachoma

Anatomical Context for Trachoma

The Foundational Model of Anatomy Ontology organs/tissues related to Trachoma:

18
Eye

MalaCards organs/tissues related to Trachoma:

38
Eye, Testes, T Cells, B Cells, Spleen

Publications for Trachoma

Articles related to Trachoma:

(show top 50) (show all 708)
# Title Authors Year
1
Prevalence of<i>Chlamydia trachomatis</i>-Specific Antibodies before and after Mass Drug Administration for Trachoma in Community-Wide Surveys of Four Communities in Nepal. ( 29141720 )
2018
2
Sanitation and water supply coverage thresholds associated with active trachoma: Modeling cross-sectional data from 13 countries. ( 29357365 )
2018
3
Interventions to maximize facial cleanliness and achieve environmental improvement for trachoma elimination: A review of the grey literature. ( 29370169 )
2018
4
Patient-centered communication of community treatment assistants in Tanzania predicts coverage of future mass drug administration for trachoma. ( 29329726 )
2018
5
Prevalence of trachoma in school children in the MarajA^ Archipelago, Brazilian Amazon, and the impact of the introduction of educational and preventive measures on the disease over eight years. ( 29447155 )
2018
6
Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. ( 29451881 )
2018
7
Prevalence of trachoma in the Kayes region of Mali eight years after stopping mass drug administration. ( 29432434 )
2018
8
Comparison of Mass Azithromycin Coverage Targets of Children in Niger: A Cluster-Randomized Trachoma Trial. ( 29260659 )
2018
9
Follow-up and report on active trachoma in Zabol, Iran, prompted by Sharifi-Rad and Fallah's observations published in May 2016. ( 29158904 )
2017
10
Active Trachoma Cases in the Solomon Islands Have Varied Polymicrobial Community Structures but Do Not Associate with Individual Non-Chlamydial Pathogens of the Eye. ( 29410954 )
2017
11
Morocco succeeds to eliminate trachoma as a public health problem: World Health Organization. ( 28584542 )
2017
12
Elimination of trachoma as a public health problem in Ghana: Providing evidence through a pre-validation survey. ( 29232708 )
2017
13
Reduced-cost Chlamydia trachomatis-specific multiplex real-time PCR diagnostic assay evaluated for ocular swabs and use by trachoma research programmes. ( 28487054 )
2017
14
Population-based prevalence survey of follicular trachoma and trachomatous trichiasis in the Casamance region of Senegal. ( 28747198 )
2017
15
Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial. ( 28893761 )
2017
16
Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati. ( 28898240 )
2017
17
Reaching remote Amazonian communities to eliminate trachoma. ( 29434443 )
2017
18
Enlightenment of blinding trachoma elimination in China. ( 29285712 )
2017
19
The Burden of and Risk Factors for Trachoma in Selected Districts of Zimbabwe: Results of 16 Population-Based Prevalence Surveys. ( 28532208 )
2017
20
Global survey of mRNA levels and decay rates of Chlamydia trachomatis trachoma and lymphogranuloma venereum biovars. ( 28795162 )
2017
21
How schools can help to build healthy, productive lives, free of trachoma. ( 29070928 )
2017
22
The Epidemiology of Trachoma in Mozambique: Results of 96 Population-Based Prevalence Surveys. ( 28910562 )
2017
23
Two Southeast Asian Countries Eliminate Trachoma. ( 29164260 )
2017
24
Serology reflects a decline in the prevalence of trachoma in two regions of The Gambia. ( 29118442 )
2017
25
Evaluation of planned bicanalicular nasolacrimal tube retention in treating punctal stenosis or occlusion secondary to trachoma. ( 28641033 )
2017
26
Active trachoma and community use of sanitation, Ethiopia. ( 28479620 )
2017
27
In Morocco, the elimination of trachoma as a public health problem becomes a reality. ( 28089329 )
2017
28
The impact of health promotion on trachoma knowledge, attitudes and practice (KAP) of staff in three work settings in remote Indigenous communities in the Northern Territory. ( 28542225 )
2017
29
Blinding trachoma among Maku Indians of the upper Rio Negro: a neglected public health problem. ( 28832733 )
2017
30
The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naA^ve trachoma-endemic island communities in West Africa. ( 29282126 )
2017
31
Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study. ( 28472466 )
2017
32
Burden of trachoma in five counties of Eastern Equatoria state, South Sudan: Results from population-based surveys. ( 28614375 )
2017
33
WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2014a892016. ( 28664685 )
2017
34
Treating village newcomers and travelers for trachoma: Results from ASANTE cluster randomized trial. ( 28662043 )
2017
35
Tracking Trachoma: How The Gambia Is Eliminating an Ancient Disease. ( 29233796 )
2017
36
The "F" in SAFE: Reliability of assessing clean faces for trachoma control in the field. ( 29190298 )
2017
37
Effect of water, sanitation and hygiene interventions on active trachoma in North and South Wollo zones of Amhara Region, Ethiopia: A Quasi-experimental study. ( 29125849 )
2017
38
Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control. ( 28722638 )
2017
39
Trachoma in the Democratic Republic of the Congo: Results of 46 Baseline Prevalence Surveys Conducted with the Global Trachoma Mapping Project. ( 28850014 )
2017
40
Trachomatous Scar Ranking: A Novel Outcome for Trachoma Studies. ( 28719271 )
2017
41
Use of validated community-based trachoma trichiasis (TT) case finders to measure the total backlog and detect when elimination threshold is achieved: a TT methodology paper. ( 28819505 )
2017
42
Integrated Mapping of Yaws and Trachoma in the Five Northern-Most Provinces of Vanuatu. ( 28118354 )
2017
43
Historical Aspects of Endemic Trachoma in Peru: 1895-2000. ( 26766118 )
2016
44
Prevalence of Trachoma in Schoolchildren in Brazil. ( 27824506 )
2016
45
Genetic Polymorphisms of TLR4 and MICA are Associated with Severity of Trachoma Disease in Tanzania. ( 27559544 )
2016
46
Arthur Ferguson MacCallan CBE, MD, FRCS (1872-1955), trachoma pioneer and the ophthalmic campaign in Egypt 1903-1923. ( 27316693 )
2016
47
Prevalence of Active and Latent Yaws in the Solomon Islands 18 Months after Azithromycin Mass Drug Administration for Trachoma. ( 27551787 )
2016
48
Prevalence of Trachoma in Car-Nicobar Island, India after Three Annual Rounds of Mass Drug Administration with Azithromycin. ( 27391274 )
2016
49
A Cross-Sectional Population-Based Survey of Trachoma among Migrant School Aged Children in Shanghai, China. ( 27610383 )
2016
50
The broad benefits of trachoma elimination. ( 27599650 )
2016

Variations for Trachoma

Expression for Trachoma

Search GEO for disease gene expression data for Trachoma.

Pathways for Trachoma

Pathways related to Trachoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.94 HLA-C KIR2DL2 KIR2DL3 TNF
2 11.89 HSPD1 IL10 TNF
3
Show member pathways
11.84 HLA-C HSPD1 IL10 KIR2DL2 KIR2DL3 TNF
4 11.82 HSPD1 IL10 TNF
5 11.78 HLA-C KIR2DL2 KIR2DL3
6
Show member pathways
11.71 HLA-C IL10 TNF
7 11.67 HLA-C KIR2DL2 KIR2DL3
8 11.5 ENG IL10 TNF
9 11.22 CTGF TNF
10
Show member pathways
11.08 IL10 TNF
11 11.05 IL10 TNF
12 10.97 IL10 TNF
13 10.88 CTGF ENG
14 10.68 IDO1 IL10 TNF

GO Terms for Trachoma

Cellular components related to Trachoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 8.92 ENG HLA-C HSPD1 TNF

Biological processes related to Trachoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.73 CTGF ENG TNF
2 immune response GO:0006955 9.73 HLA-C IL10 KIR2DL3 TNF
3 regulation of immune response GO:0050776 9.71 HLA-C KIR2DL2 KIR2DL3
4 positive regulation of protein phosphorylation GO:0001934 9.63 CTGF ENG TNF
5 positive regulation of interleukin-6 production GO:0032755 9.61 HSPD1 TNF
6 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.6 CTGF TNF
7 positive regulation of interferon-gamma production GO:0032729 9.59 HSPD1 TNF
8 negative regulation of T cell proliferation GO:0042130 9.58 IDO1 IL10
9 B cell proliferation GO:0042100 9.58 HSPD1 IL10
10 negative regulation of mitotic cell cycle GO:0045930 9.57 IL10 TNF
11 positive regulation of cytokine secretion GO:0050715 9.55 IL10 TNF
12 negative regulation of interleukin-6 production GO:0032715 9.52 IL10 TNF
13 positive regulation of interleukin-12 production GO:0032735 9.51 HSPD1 IDO1
14 positive regulation of collagen biosynthetic process GO:0032967 9.49 CTGF ENG
15 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.48 IL10 TNF
16 positive regulation of macrophage activation GO:0043032 9.4 HSPD1 IL10
17 negative regulation of growth of symbiont in host GO:0044130 9.37 IL10 TNF
18 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.32 IL10 TNF
19 endothelial cell apoptotic process GO:0072577 9.26 IL10 TNF
20 negative regulation of cytokine secretion involved in immune response GO:0002740 9.16 IL10 TNF
21 receptor biosynthetic process GO:0032800 8.96 IL10 TNF
22 extracellular matrix constituent secretion GO:0070278 8.62 CTGF ENG

Sources for Trachoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....